Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

2.68
-0.1400-4.96%
Post-market: 2.700.0200+0.75%19:35 EDT
Volume:2.80M
Turnover:7.75M
Market Cap:297.48M
PE:-1.28
High:2.95
Open:2.79
Low:2.63
Close:2.82
52wk High:3.78
52wk Low:0.9857
Shares:111.00M
Float Shares:86.04M
Volume Ratio:1.41
T/O Rate:3.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1000
EPS(LYR):-2.1000
ROE:-126.98%
ROA:-61.49%
PB:2.65
PE(LYR):-1.28

Loading ...

Cabaletta Bio Insiders Go on a Buying Spree, Signaling Strong Confidence From the Top

TIPRANKS
·
Jan 22

Cabaletta Bio CEO Steven Nichtberger Reports Acquisition of Common Shares

Reuters
·
Jan 22

Cabaletta Bio Director Mark Simon Reports Acquisition of Common Shares

Reuters
·
Jan 22

Cabaletta Bio announces 2026 strategic priorities

TIPRANKS
·
Jan 12

Cabaletta Bio Outlines 2026 Strategy Focused on Enrolling Pivotal Myositis Trial, Advancing Outpatient and No Preconditioning Rese-cel Therapies, and Scaling Automated Manufacturing for Autoimmune Disease Pipeline

Reuters
·
Jan 12

Press Release: Cabaletta Bio Announces 2026 Strategic Priorities

Dow Jones
·
Jan 12

FDA Clears IND Amendment for Cabaletta Bio’s Rese-cel Clinical Manufacturing

Reuters
·
Jan 12

Ind Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms

THOMSON REUTERS
·
Jan 12

Cabaletta Bio Unveils Plans for CD19 Cell Therapies Targeting Autoimmune Diseases

Reuters
·
Dec 07, 2025

Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)

TIPRANKS
·
Nov 14, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio Advances in Autoimmune Therapy Development

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio reports smaller-than-expected Q3 loss

Reuters
·
Nov 10, 2025

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

TIPRANKS
·
Nov 10, 2025

Cabaletta Bio Q3 EPS $(0.44) Beats $(0.45) Estimate; Cash, Cash Equivalents And Short-Term Investments Of $159.9M Provides Cash Runway Into 2H 2026

Benzinga
·
Nov 10, 2025

Cabaletta Bio sees cash runway into 2H26

TIPRANKS
·
Nov 10, 2025

Cabaletta Bio Reports Q3 2025 Financial Results and Advances Rese-cel Clinical Programs

Reuters
·
Nov 10, 2025

Cabaletta Bio posts Q3 research and development expenses of $39.8 million

Reuters
·
Nov 10, 2025